TD Cowen ATS 2026 Planner

Research evidence excerpt

TD Cowen ATS 2026 Planner

ntitrypsin Deficiency (AATD) Emphysema: Results From Phase 2 ElevAATe Trial W304WestA-D Concourse)(Level III, OCCC

18-May 2:15-4:15 Posters: Emerging Therapies in Bronchiectasis and Related Infections: The New Frontier

Non-CF Bronchiectasis Occurrence, Exacerbation Rates, and Inhaled Antibiotic Use in the U.S.: A Population-based Descriptive Analysis 405

W230 (Level II, OCCC West academic

Patient and Caregiver Survey of Burden of Bronchiectasis in US and Europe 406 INSM Concourse)

Long-term Impact of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients With ≥1 F508del Mutation: Results From Four Years of Real-world Data 416 academic

18-May 2:15-4:15 Posters: Clinical and Epidemiological Insights into Pulmonary Hypertension: Trends, Treatments, and Outcomes

Efficacy and Safety of Sotatercept in Patients With Pulmonary Arterial Hypertension (PAH) Classified as Intermediate-low Risk: A Pooled Analysis From PULSAR, STELLAR, and HYPERION 1005 MRK

Real-world Persistence to Oral Treprostinil in Patients With Pulmonary Arterial Hypertension: A Decade in Review 1010 UTHR

Population Pharmacokinetics Analysis of Treprostinil Using Data From Phase 1 and 2 Studies of Treprostinil Palmitil Inhalation Powder 1014 W414CD (Level IV, OCCC West INSM

Safety and Efficacy of Sotatercept in Pulmonary Arterial Hypertension Patients With Comorbidities 1021 Concourse) academic

A Real-world Registry of Sotatercept in Pulmonary Arterial Hypertension: The Mayo Clinic Experience 1023 academic

Clinical Outcomes and Safety of Sotatercept in Pulmonary Arterial Hypertension: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials 1024 academic

18-May 2:15-4:15 Fibrosis, Cough, and Inflammation: Treatment Strategies in ILD (ORAL)